Dr. Jay Yaakov Spiegel, MD

Dr. Spiegel practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Spiegel's NPI, 1932551066, was assigned on July 13, 2016. Dr. Spiegel graduated from Georgetown University School Of Medicine in 2014. Dr. Spiegel's Florida license number on file is 1842.

Dr. Spiegel's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Spiegel's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spiegel practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Spiegel's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Spiegel is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Spiegel's licenses on file in 2 states: Florida and California.

Dmand AI lists lymphoma among the conditions Dr. Spiegel treats.

CMS data shows 111 Medicare services from Dr. Spiegel across 3 procedure codes in 2024, for 38 Medicare patients. Medicare paid $11,572 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 38 Medicare patients who saw Dr. Spiegel in 2024. The largest group is 65 to 74, with 17 patients. 74% of them have high blood pressure, and 71% have high cholesterol. 39% are also on Medicaid. Their average risk score is 3.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spiegel's median patient age at 66, with 43% women.

In 2024, Dr. Spiegel wrote 41 Medicare Part D claims for 15 patients. 76% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $212 in total drug cost. In 2021, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Spiegel for performance year 2024, reported as part of a group. Dr. Spiegel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spiegel as offering telehealth.

Dmand AI links 23 papers to Dr. Spiegel, published from 2016 to 2025. 2024 was the busiest year, with 3. The most frequent topics are Immunotherapy, Adoptive, Receptors, Chimeric Antigen and Lymphoma, Large B-Cell, Diffuse. Dr. Spiegel has published most often in Blood Adv. Dr. Spiegel's most frequent co-authors are David Bernard Miklos, MD, PhD, Krishna Komanduri, DO and Krishna V. Komanduri, MD.

Dmand AI links Dr. Spiegel to 4 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Lymphoma, B-Cell, Marginal Zone and Multiple Myeloma.

CMS Open Payments shows 18 general payments to Dr. Spiegel from 4 drug and device companies from 2023 to 2025. Consulting fees make up the largest share, 86% of the total. Gilead Sciences, Inc. paid the most, $10,515.

Dr. Spiegel graduated from Georgetown University School Of Medicine in 2014.

Dr. Spiegel is in network with 10 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.